AYTU - アイトゥ・バイオサイエンス (Aytu BioScience Inc.) アイトゥ・バイオサイエンス

 AYTUのチャート


 AYTUの企業情報

symbol AYTU
会社名 Aytu BioScience Inc (アイトゥ・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aytu BioScience Inc. is a commercial-stage healthcare company focused on acquiring developing and commercializing products in the field of urology. The Company focuses on hypogonadism prostate cancer urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide) a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company''s pipeline includes MiOXSYS an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone) a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company through its wholly-owned subsidiary Nuelle Inc. is focused on women’s sexual wellbeing and intimacy.   アイトゥ・バイオサイエンスは米国のバイオ医薬品企業。泌尿器科の疾患に対する治療薬の開発・商業化に従事する。性腺機能低下症、泌尿器科のがん、男性不妊症、男性の健康における医療ニ―ズに焦点を置く。テストステロン製剤の鼻用ゲル「Natesto」、前立腺がん検出用の「ProstaScint」を開発する。本社所在地はコロラド州イ―グルウッド。   
本社所在地 373 Inverness Parkway Suite 206 Englewood CO 80112 USA
代表者氏名 Joshua R. Disbrow ジョシュア・R・ディスブロー
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +1 720-437-6580
設立年月日 37469
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 63人
url www.aytubio.com
nasdaq_url https://www.nasdaq.com/symbol/aytu
adr_tso
EBITDA EBITDA(百万ドル) -15.25294
終値(lastsale) 1.19
時価総額(marketcap) 2143679.09
時価総額 時価総額(百万ドル) 11.87358
売上高 売上高(百万ドル) 3.66012
企業価値(EV) 企業価値(EV)(百万ドル) 4.86105
当期純利益 当期純利益(百万ドル) -10.18786
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Aytu Bioscience Inc revenues increased 14% to $3.7M. Net loss decreased 55% to $10.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Derivative income increase from $213K to $4M (income) Interest (expense) decrease of 70% to $749K (expense).

 AYTUのテクニカル分析


 AYTUのニュース

   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   Aytu BioScience EPS beats by $0.01, beats on revenue (NASDAQ:AYTU)  2020/10/06 20:07:28 Seeking Alpha
Aytu BioScience (NASDAQ:AYTU): Q4 GAAP EPS of -$0.03 beats by $0.01. Revenue of $14.86M (+764.0% Y/Y) beats by $3.62M. Shares +19.55%. Press Release
   Aytu BioScience's Earnings Outlook  2020/09/23 10:26:00 Benzinga
On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings …
   Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study  2020/08/17 12:00:00 Yahoo Finance
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
   Aytu BioScience EPS beats by $0.01, beats on revenue (NASDAQ:AYTU)  2020/10/06 20:07:28 Seeking Alpha
Aytu BioScience (NASDAQ:AYTU): Q4 GAAP EPS of -$0.03 beats by $0.01. Revenue of $14.86M (+764.0% Y/Y) beats by $3.62M. Shares +19.55%. Press Release
   Aytu BioScience's Earnings Outlook  2020/09/23 10:26:00 Benzinga
On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings …
   Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study  2020/08/17 12:00:00 Yahoo Finance
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy  2020/06/25 16:00:04 Yahoo Finance
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
   Aytu BioScience EPS beats by $0.01, beats on revenue (NASDAQ:AYTU)  2020/10/06 20:07:28 Seeking Alpha
Aytu BioScience (NASDAQ:AYTU): Q4 GAAP EPS of -$0.03 beats by $0.01. Revenue of $14.86M (+764.0% Y/Y) beats by $3.62M. Shares +19.55%. Press Release
   Aytu BioScience's Earnings Outlook  2020/09/23 10:26:00 Benzinga
On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings …
   Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study  2020/08/17 12:00:00 Yahoo Finance
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy  2020/06/25 16:00:04 Yahoo Finance
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイトゥ・バイオサイエンス AYTU Aytu BioScience Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)